Novel Dual Soft Drug Strategy Enables Development of Topical Androgen Receptor Antagonists with Enhanced Efficacy and Optimized Safety for Androgenetic Alopecia

The study presents a novel dual soft drug strategy for developing topical androgen receptor (AR) antagonists to treat androgenetic alopecia (AGA) with enhanced efficacy and optimized safety. The research focused on improving the first-generation AR antagonist 14-P1 by refining its structure to enhance AR antagonism. The resulting candidate, compound 39, demonstrated potent AR antagonism with an IC 50 of 20.6 ± 2.3 nM and favorable pharmacokinetic profiles. In a hair-growth mouse model, 0.5% of compound 39 showed comparable efficacy to 0.5% pyrilutamide but with faster response kinetics (14-day vs 21-day onset) and maintained safety. This approach effectively balances therapeutic potency with a low risk of systemic toxicity, offering a promising direction for future topical AR antagonist development.